Literature DB >> 23500204

Combined treatment with gabapentin and drugs affecting the renin-angiotensin system against electroconvulsions in mice.

Krzysztof Lukawski1, Agnieszka Janowska, Tomasz Jakubus, Grzegorz Raszewski, Stanisław J Czuczwar.   

Abstract

Recent experimental data suggest that certain angiotensin-converting enzyme (ACE) inhibitors and angiotensin AT1 receptor antagonists may possess anticonvulsant activity. The purpose of this study was to examine the effects of two ACE inhibitors, captopril and enalapril, and two AT1 receptor antagonists, losartan and telmisartan, on the protective action of gabapentin in the maximal electroshock seizure threshold test in mice. Additionally, the effects of the combined treatment with gabapentin and antihypertensive drugs on memory retention in the passive avoidance task and motor coordination in the chimney test were assessed. All drugs were injected intraperitoneally. Losartan (50mg/kg) significantly increased the convulsive threshold for gabapentin. The other antihypertensive drugs, captopril (50mg/kg), enalapril (30 mg/kg) and telmisartan (30 mg/kg), did not affect the anticonvulsant activity of gabapentin. The observed interaction between gabapentin and losartan could be pharmacokinetic in nature. Losartan increased plasma and total brain concentrations of gabapentin. In the chimney test, losartan (50mg/kg) administered with gabapentin (50mg/kg) caused motor impairment. In the passive avoidance test, memory retention was not affected by the combined treatment with gabapentin and antihypertensive drugs. It is suggested that the use of captopril, enalapril and telmisartan in epileptic patients receiving gabapentin is presumed neutral upon its anticonvulsant action. The utmost caution is advised when combining losartan and gabapentin in clinical practice due to the appearance of pharmacokinetic interactions between losartan and gabapentin as well as motor impairment evoked by these drugs in mice.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23500204     DOI: 10.1016/j.ejphar.2013.02.054

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

2.  Evaluation and comparison of anticonvulsant activity of telmisartan and olmesartan in experimentally induced animal models of epilepsy.

Authors:  Pushpa V H; Padmaja Shetty K; Suresha R N; Jayanthi M K; Ashwini V; Vaibhavi P S
Journal:  J Clin Diagn Res       Date:  2014-10-20

Review 3.  Review about gabapentin misuse, interactions, contraindications and side effects.

Authors:  Gabriel C Quintero
Journal:  J Exp Pharmacol       Date:  2017-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.